INTRODUCTION miRNAs are a class of endogenous and evolutionarily conserved noncoding small RNAs (approximately 22 nucleotides) that bind to the 3 0 untranslated regions of target genes. Once bound, miRNAs repress target gene translation and/or induce the degradation of the target gene mRNA. 1 miRNAs are ubiquitously expressed in a wide range of species, including viruses, worms, flies, plants and animals. 2, 3 It is estimated that 1000 miRNAs are encoded in the human genome and expressed in a tissue-and cell type-specific manner. An individual miRNA can target numerous other mRNAs and can itself be targeted by multiple miRNAs, resulting in a vast regulatory potential. 4 miRNAs have been shown to have fundamental roles in diverse biological and pathological processes, including intracellular signaling pathways, organ morphogenesis and disease processes. 5 The aberrant expression of miRNAs is closely associated with the initiation and progression of pathophysiologic processes. 4 It has been shown that extracellular miRNAs circulating in the blood can be measured. Most circulating miRNAs are found in lipid or lipoprotein complexes, such as apoptotic bodies, microvesicles, exosomes and other extracellular vesicles, resulting in a high degree of miRNA stability despite the presence of ribonucleases in both plasma and serum. 6 The existence of miRNAs circulating in the blood has raised the possibility that miRNAs may possess the capability to serve as novel biomarkers. Recent reports have demonstrated that miRNAs represent potential biomarkers with distinct clinical characteristics, such as disease diagnosis or activity. 7 Scleroderma (systemic sclerosis, SSc) is a complex heterogeneous autoimmune disease of unknown etiopathogenesis. SSc is characterized by vascular dysfunction and the excessive accumulation of the extracellular matrix (ECM), resulting in the progressive fibrotic replacement of normal tissue architecture and leading to the failure of affected organs, such as the kidney, heart and lung. 8 The exact cellular and molecular mechanism of SSc remains unclear, but it involves complex interactions among vascular, immune and fibrotic processes in association with a genetic predisposition. 9 To date, no therapy has been shown to reverse or arrest the progression of fibrosis, representing a major unmet medical need.
The selective targeting of the molecules and pathways that are involved in fibroblast activation, either singly or in combination, may offer new approaches in the treatment of fibrosis. The elevated expression of profibrotic miRNAs and/or reduced expression of antifibrotic miRNAs are likely to be important factors in the development of fibrosis in SSc patients. The regulation of miRNA expression could be therapeutically exploited to offer new treatments for SSc, and miRNAs circulating in the blood represent potential biomarkers for fibrosis.
In this review, we summarize recent advances in identifying the specific miRNAs involved in SSc pathogenesis, underscored by the potential use of specific miRNAs as novel biomarkers and therapeutic targets for the future management of SSc patients.
miRNA EXPRESSION SIGNATURE IN SSc FIBROSIS miRNA expression profiles have been successfully utilized in the classification of human cancer, heart disease and autoimmune diseases. Studies of miRNA expression profiles in patients with SSc are expected to result in similar findings, revealing a biological and clinical relevance between miRNA expression and SSc disease state and severity. In our previous study, we identified the unique miRNA expression signature present in SSc skin samples. The two major subgroups of SSc, diffuse cutaneous scleroderma (dSSc) and limited cutaneous scleroderma (lSSc), displayed different miRNA expression signatures. We identified 42 miRNAs that were differentially expressed in dSSc and 60 miRNAs with altered expression in lSSc. A total of 21 miRNAs displaying altered expression in SSc skin samples were common between dSSc and lSSc. Among these miRNAs with changed expression, many were predicted to function as inhibitors of numerous mRNAs involved in autoimmune, vascular and fibrotic processes. 10 Using miRNA microarray analysis, Li et al. 11 identified 24 differentially expressed miRNAs from patients with SSc, including 9 upregulated miRNAs and 15 downregulated miRNAs. Through bioinformatics analysis and literature retrieval, they identified the target genes regulated by six of the miRNAs whose differential expression was correlated with SSc pathogenesis and hypothesized that the abnormal expression of some miRNAs may be important molecular events during the process of SSc genesis, development and evolution. 11 The overlap between the miRNA expression signature identified in our study, which examined patients with SSc, and the signature identified in Li's study is relatively limited. In our study, we used skin samples from four patients with dSSc, two patients with lSSc, and three healthy volunteers as normal controls for miRNA array analysis. In Li's study, skin samples from three patients with SSc (the authors did not mention the SSc subgroups) and three healthy control volunteers were used for miRNA array analysis. The difference between the two studies can be explained by diversity in the disease severity, medical history and ethnicity of SSc patients, miRNA profiles of specific cell-types, and even more specifically, the developmental and functional organ status. 12 Both our and Li's study revealed the unique miRNA expression signature in SSc patients, demonstrating that many of the dysregulation miRNAs exerted pro-or antifibrotic effects and participated in fibrosis.
miRNAs DYSREGULATED IN SSc FIBROSIS
Immune perturbations and vascular injury precede and contribute to the development of fibrosis in SSc, which, in turn, further exacerbate vascular and immune damage. 9 Tissue fibrosis is the hallmark of SSc and is responsible for most SSc clinical manifestations. Microarray and real-time PCR analysis has shown that approximately 40 miRNAs are linked to fibrosis in various organs and disease settings. Most of these miRNAs are regulated by transforming growth factor (TGF)-b, which has been considered a crucial participant in the pathogenesis of the SSc fibrotic process. Many miRNAs have been shown to participate in repairing and remodeling the matrix including collagens, matrix metalloproteinases and integrins. miR-133, miR-141, miR-200a/b, miR-21 and miR-590 have been shown to directly induce or inhibit fibrosis by targeting the TGF-b/Smad canonical signaling pathway. [13] [14] [15] [16] [17] [18] An analysis of miR-132, miR-133 and the miR-17-92 cluster (miR-18a, 19a/b) revealed that their targets were connective tissue growth factor. [19] [20] [21] [22] miR-29a/b/c, miR-377 (clustered with miR-382) and miR-449a/b have shown to be involved with ECM structural proteins or enzymes active in ECM remodeling. [23] [24] [25] [26] [27] [28] [29] let7, miR-132, miR-155, miR-192 and miR-382 have been implicated in indirectly regulating fibrogenesis by affecting the epithelial-to-mesenchymal transition 19, [30] [31] [32] [33] [34] [35] [36] while miR-132, miR-15b, miR-16, miR-150, miR-27a, miR-27b, miR-335 and miR-34a were found to induce myofibroblast proliferation and resistance to apoptosis. 19,37-42 miR-29 As described above, many miRNAs are involved in fibrosis. Among these, miR-29 has been extensively studied and is the best characterized direct regulator of ECM synthesis. 43, 44 miR-29 exerts antifibrotic effects in several major fibrotic disorders, including SSc. miR-29 is known to directly repress the expression of collagen I, collagen III and collagen IV. Platelet-derived growth factor-B and TGF-b can downregulate miR-29a expression, leading to the further upregulation of plateletderived growth factor-B and TGF-b. This positive feedback loop can lead to the uncontrolled accumulation of ECM proteins. 44 Evidence has suggested that a strong downregulation of miR-29 expression in tissues and cells can cause a fibrotic response, including cardiac, pulmonary and liver fibrosis.
miR-29 was shown to negatively regulate COL1A1, COL1A2, COL3A1, FBN1 and ELN1 gene expression and to be responsible for ECM synthesis in myocardial infarction. 24 In lung fibrosis, miR-29 targeted many fibrosis-associated genes, including both structural ECM genes and enzymes involved in tissue remodeling. miR-29 levels were inversely correlated with the severity of fibrosis. 25 In carbon tetrachloride-induced hepatic fibrogenesis mice, the miR-29 family was found to be significantly decreased in livers. The overexpression of miR-29b in a mouse model resulted in protection against salt-induced hypertensive renal medullary fibrosis after a highsalt diet. The silencing of miR-29b in the kidney of these animals caused the upregulation of a large number of ECM and ECM-modulating genes. 26 Studies investigating the role of miR-29 in SSc are ongoing. Our previous study demonstrated that miR-29 was decreased in both SSc skin tissues and primary fibroblasts. The downregulation of miR-29 was correlated with the upregulation of COL1A1 mRNA. 10 Maurer et al. 23 identified miR-29 as a key regulator of collagen expression in SSc. In their study, miR-29 was downregulated in cultured dermal fibroblasts derived from SSc skin, resulting in excessive collagen production. In a bleomycin-induced mouse model of skin fibrosis, the tyrosinekinase inhibitor imatinib mesylate was shown to inhibit the platelet-derived growth factor-B and TGF-b pathways and restore miR-29a levels. The supplementation of miR-29a decreased collagen expression in SSc fibroblasts. In addition, serum miR-29a levels were found to be significantly decreased in the very early stage of SSc. 45 All of these studies suggest that miR-29 expression was downregulated by TGF-b and that decreased miR-29 expression was involved in SSc tissue fibrosis. Other signaling pathways also involve miR-29, such as the Wnt/b-catenin, nuclear factor-kappaB (NF-kB) and mitogen-activated protein kinases pathways. 43 miR-29 could participate in other biological pathways involved in the fibrosis process.
OTHER miRNAs
In addition to miR-29, there are many other miRNAs known to undergo SSc fibrosis regulation, (Table 1) . Our preliminary data showed that miR-21 was increased and that miR-145 was decreased in both SSc skin tissues and fibroblasts. After stimulation with TGF-b, the expression of miR-21 was increased and that of Smad7 mRNA was decreased. miR-145 was also upregulated, whereas Smad3 mRNA levels were downregulated. miR-21 and miR-145 may exert pro-or antifibrosis effects in SSc. 10 Further, we studied the direct one-toone relationship between miR-21 and Smad7. We found that Smad7 was a direct target of miR-21 and that miR-21 was induced by TGF-b, which in turn promoted the TGF-binduced fibrogenic activation of skin fibroblasts through the targeting of Smad7 (data not shown). Honda et al. 46 demonstrated decreased miR-150 expression in SSc fibroblasts both in vivo and in vitro. The transfection of a miR-150 inhibitor into normal fibroblasts induced the expression of integrin b3, phosphorylated Smad3 and COL1A1, whereas the forced overexpression of miR-150 resulted in the downregulation of these genes in SSc fibroblasts. miR-150 was shown to have an important role in the pathogenesis of SSc. miR-196a directly contributed to the constitutive upregulation of COL1A1 and COL1A2 expression in SSc fibroblasts. The DDR2-miR-196a pathway was a negative feedback system and impairment of this pathway may be involved in the pathogenesis of SSc. 47 The inhibition of miR-196a led to the overexpression of COL1A1 and COL1A2 in normal fibroblasts, whereas the overexpression of miR-196a resulted in the downregulation of COL1A1 and COL1A2 in SSc fibroblasts. 48 Compared with untreated normal fibroblasts, miR-92a expression was significantly increased in TGF-btreated normal cultured dermal fibroblasts and SSc fibroblasts. The overexpression of miR-92a in normal fibroblasts resulted in the downregulation of MMP-1 expression. 49 The miRNAs described above exert pro-or antifibrotic effects in SSc through different signaling pathways. They may be common regulators of fibrosis in different organs and disease settings. Inhibiting the function of these miRNAs through the use of anti-miR oligonucleotides, small-molecule inhibitors, miRNA sponges and miRNA masks/target protectors and promoting the activity of antifibrotic miRNAs through gene therapy or delivery of miRNA mimics can serve as novel therapeutic options in the treatment of fibrosis.
miRNA AS BIOMARKERS IN SSc
Fibrosis is the most important and prominent clinical feature of SSc and occurs in multiple organs. The extent and severity of tissue fibrosis correlates with prognosis and mortality in SSc. However, there is an unmet need for reliable and accurate biomarkers that reflect the fibrotic process in SSc. Serum miRNA levels can be used as valuable biomarkers for the diagnosis, prognosis and therapeutic value of various diseases. The expression pattern of miRNAs is reflective of the underlying pathophysiologic processes specific to various disease states. Disease-associated miRNAs can be measured from various sources, such as blood components, biologic fluids and tissue samples. 50 miRNAs are highly stable and appear to be resistant to variations in sample handling (they can even be detected in formalin-fixed paraffin-embedded samples by microarray profiling or in situ hybridization), which increase 50 Good correlations between serum and tissue miRNA profiles have already been shown for several cancers and various other diseases. Reports suggest that miRNAs have important roles in systemic rheumatic diseases. Various diseases and different stages of the same disease are associated with distinct miRNA expression profiles. 7 The biomarker potential of many serum miRNAs has been investigated in patients with SSc. The elevated expression of profibrotic miRNAs and/or reduced expression of antifibrotic miRNAs are likely to be important factors in the development of fibrosis in SSc. Circulating miRNAs are promising biomarker candidates for the diagnosis, prognosis and assessment of disease activity and severity ( Table 2) . Serum miR-150 levels were found to be decreased in SSc patients, and SSc patients with lower serum miR-150 levels had more severe clinical manifestations. 46 Patients with lower serum miR-196a levels had a significantly higher ratio of dSSc:lSSc, a higher modified Rodnan total skin thickness score, and a higher prevalence of pitting scars than those with higher miR-196a levels. 48 Serum levels of miR-92a were significantly higher in SSc patients than in normal subjects, and patients with increased miR-92a levels tended to have telangiectasia at a lower frequency than those with normal levels. 49 Makino et al. 51 collected serum samples from 61 patients with SSc, 8 patients with systemic lupus erythematosus, 8 patients with dermatomyositis, 12 patients with scleroderma spectrum disorder and 20 healthy controls. Analysis of the samples by realtime PCR indicated that the miR-142-3p levels in patients with SSc were significantly higher than those in patients with systemic lupus erythematosus, dermatomyositis, scleroderma spectrum disorder (SSD) and healthy control subjects. The serum levels of miR-142-3p were correlated with the severity of SSc fibrosis and may be useful diagnostic markers for the presence of SSc and differentiation of SSc from scleroderma spectrum disorder.
COL1A1 is a target of miR-29a and is upregulated in SSc patients. Kawashita et al. 45 also determined miR-29a levels in serum samples from 61 SSc patients. Serum miR-29a levels were not downregulated in SSc, and there was no statistically significant difference between healthy control subjects and SSc patients. However, SSc patients with reduced miR-29a levels had significantly higher right ventricular systolic pressure by Doppler echocardiography than those with normal miR-29a levels. Although the cause of pulmonary hypertension in SSc is still uncertain, this result suggested that miR-29a also has a role in the pathogenesis of pulmonary hypertension. 45 CONCLUSIONS miRNAs are important post-transcriptional regulators that may repress more than 60% of all mammalian protein-coding genes. 52, 53 They are strongly associated with the pathogenesis of a wide range of human diseases. Disease-associated miRNAs represent a new class of targets for the development of miRNA-based therapeutic modalities, which may yield patient benefits that are unobtainable using other therapeutic approaches. As outlined in this review, there is increasing evidence that miRNAs have a role in the regulation of fibrosis in SSc patients. Similar to antisense molecules that have been used therapeutically for fibrosis, the use of miRNA as a therapeutic target provides theoretical advantages over the current drug design strategies in SSc fibrosis, which are focused on single-gene targeting. The specific inhibition of a miRNA or the addition of a single miRNA mimetic may produce a phenotype that is derived from a complex set of gene expression changes. Clinical results with miR-122 inhibition in HCV patients validate the concept that miRNA modulation in humans is possible. 54 Although the field of miRNA therapeutics is in its infancy, promising data in both laboratory animals and in humans already exist. 55 Because miRNAs exhibit remarkable stability, as well as an ease and reliability of detection, miRNAs from blood samples or urine samples of patients hold promise as novel noninvasive clinical biomarkers, especially for early diagnosis. 56 Provocative ideas on miRNA and its role in the pathogenesis of diverse autoimmune diseases including SSc have been put forward. The identification of specific miRNAs as biomarkers of disease severity will pave the way for the development of disease-and stage-specific targeted therapies.
REVIEW CRITERIA
A search for original articles published between 2007 and 2013 was performed using the PubMed database. The search terms used were 'microRNA,' 'fibrosis,' 'SSc or scleroderma or systemic sclerosis' and 'precursor and process,' alone and in combination. All articles identified were full-text English- 
CONFLICT OF INTEREST
The authors declare no conflict of interest.
